Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Reumatismo ; 72(2): 75-85, 2020 Jul 23.
Artículo en Inglés | MEDLINE | ID: mdl-32700873

RESUMEN

The aim of this study was to promote the construction of a real network and a shared diagnostic and therapeutic management model between hospitals and out-of-hospital healthcare services to capture as many patients with bone fragility as possible. Starting from the analysis of the clinical competences present in the province of Pavia, the bone specialists (BSs) organized some educational events involving both general practitioners (GPs) and hospital specialists. The Fracture Liaison Service (FLS) model, the revision of Note 79, the national plan for chronicity and the health reform of the Lombardy Regional Authority supported the structure of our model, in which the roles of clinicians are well defined and based on the complexity and severity of patients. In our method the GP has a central role as clinical manager, facilitating patient management and communication between the specialists and the BS. In January 2019, the Therapeutic Care Diagnostic Path (PDTA) shared between 2 bone specialists (BSs), 9 GPs, as reference treaters, and a multidisciplinary group of 25 specialists of the Province of Pavia was defined. The strategic directions of the two largest public hospitals in Pavia have supported the PDTA, which was validated by the quality departments of the hospitals themselves. Finally, sixty GPs belonging to the network have joined the PDTA. This model is the first example of integrated management between hospitals and out-of-hospital healthcare services for the primary and secondary prevention of fragility fractures (FF), where the GPs play a pivotal role as managers and supervisors to ensure proper care to chronic patients according to their levels of severity.


Asunto(s)
Fracturas Óseas/etiología , Fracturas Óseas/prevención & control , Modelos Teóricos , Osteoporosis/complicaciones , Prevención Primaria , Prevención Secundaria , Adulto , Femenino , Hospitales , Humanos , Comunicación Interdisciplinaria , Persona de Mediana Edad , Índice de Severidad de la Enfermedad
2.
J Hosp Infect ; 110: 33-36, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33516798

RESUMEN

COVID-19 is a global health threat with a huge number of confirmed cases and deaths all over the world. Human-to-human transmission via respiratory droplets and contact with aerosol-infected surfaces are the major routes of virus spread. Because SARS-CoV-2 can remain in the air and on surfaces from several hours to several days, disinfection of frequently touched surfaces and critical rooms, in addition to observing individual hygiene tips, is required to reduce the virus spreading. Here we report on an investigation into the use of gaseous ozone as a potentially effective sanitizing method against the new coronavirus.


Asunto(s)
COVID-19/prevención & control , COVID-19/transmisión , Desinfección/métodos , Viabilidad Microbiana/efectos de los fármacos , Ozono , SARS-CoV-2/efectos de los fármacos , Aerosoles , Humanos
5.
Chemioterapia ; 5(5): 327-9, 1986 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-3791480

RESUMEN

The pharmacokinetics of netilmicin after i.v. administration were studied in 10 adult hemodialyzed patients during and after a dialysis session. The mean interdialysis half-life was 49.6 h, whereas during dialysis this value was reduced to 5.02 h. The mean volume of distribution of netilmicin was about 20% of the total body weight. The dialyzer clearance of netilmicin, measured at 60 and 150 min after the beginning of the session, was about 50 ml/min; this means that 60-65% of the drug may be lost during the 4.5 h standard dialysis. The total body clearance of netilmicin was similar to the dialyzer clearance values, suggesting that the drug is eliminated almost entirely by hemodialysis and that its renal elimination in our patients is negligible. In conclusion, in uremic hemodialyzed patients netilmicin behaves like other aminoglycosides.


Asunto(s)
Netilmicina/metabolismo , Diálisis Renal , Uremia/metabolismo , Semivida , Humanos , Cinética , Netilmicina/efectos adversos , Netilmicina/sangre , Uremia/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA